Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

• Status: Recruiting
• Trial end date: 2025-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open label phase II pilot study assessing the metabolomic and inflammatory effects of oral aspirin (ASA) in human subjects at risk for melanoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Utah
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Must have at least 2 nevi (each >5 mm diameter) not clinically suspicious for melanoma that can be biopsied.

• Must be older than age 18.

• Must be able to receive informed consent and sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

• The patient is a minor, under age 18.

• The patient cannot speak / understand English or Spanish.

• The patient is pregnant or breastfeeding.

• The patient is a prisoner, critically or mentally ill, or otherwise incapacitated or considered vulnerable.

• The patient has history of allergic reaction to ASA.

• The patient has history of severe asthma.

• The patient has been taking ASA or any NSAID in the past 2 weeks.

• The patient has been taking a blood thinner in the past 2 weeks.

• The patient has history of bleeding disorder.

• The patient has history of peptic ulcer disease.

• The patient has had recent intense UV exposure in the past month.